Europe Filgrastim Market Size & Competition Analysis, 2027

Europe Filgrastim Market By Drug Type (Biosimilar and Biologic), By Indication (Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027

Published Date: December-2021 | Number of Pages: 82 | Format: PDF | Report ID: KBV-16052

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Filgrastim Market, by Drug Type
1.4.2 Europe Filgrastim Market, by Indication
1.4.3 Europe Filgrastim Market, by Distribution Channel
1.4.4 Europe Filgrastim Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Europe Filgrastim Market by Drug Type
3.1 Europe Biosimilar Market by Country
3.2 Europe Biologic Market by Country

Chapter 4. Europe Filgrastim Market by Indication
4.1 Europe Chemotherapy induced Neutropenia Market by Country
4.2 Europe Chronic Neutropenia Market by Country
4.3 Europe Other Indications Market by Country

Chapter 5. Europe Filgrastim Market by Distribution Channel
5.1 Europe Hospital Pharmacies Market by Country
5.2 Europe Retail Pharmacies Market by Country
5.3 Europe Online Pharmacies Market by Country

Chapter 6. Europe Filgrastim Market by Country
6.1 Germany Filgrastim Market
6.1.1 Germany Filgrastim Market by Drug Type
6.1.2 Germany Filgrastim Market by Indication
6.1.3 Germany Filgrastim Market by Distribution Channel
6.2 UK Filgrastim Market
6.2.1 UK Filgrastim Market by Drug Type
6.2.2 UK Filgrastim Market by Indication
6.2.3 UK Filgrastim Market by Distribution Channel
6.3 France Filgrastim Market
6.3.1 France Filgrastim Market by Drug Type
6.3.2 France Filgrastim Market by Indication
6.3.3 France Filgrastim Market by Distribution Channel
6.4 Russia Filgrastim Market
6.4.1 Russia Filgrastim Market by Drug Type
6.4.2 Russia Filgrastim Market by Indication
6.4.3 Russia Filgrastim Market by Distribution Channel
6.5 Spain Filgrastim Market
6.5.1 Spain Filgrastim Market by Drug Type
6.5.2 Spain Filgrastim Market by Indication
6.5.3 Spain Filgrastim Market by Distribution Channel
6.6 Italy Filgrastim Market
6.6.1 Italy Filgrastim Market by Drug Type
6.6.2 Italy Filgrastim Market by Indication
6.6.3 Italy Filgrastim Market by Distribution Channel
6.7 Rest of Europe Filgrastim Market
6.7.1 Rest of Europe Filgrastim Market by Drug Type
6.7.2 Rest of Europe Filgrastim Market by Indication
6.7.3 Rest of Europe Filgrastim Market by Distribution Channel

Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Amgen, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.3 Pfizer, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.4 Novartis AG
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Dr. Reddy’s Laboratories Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.5.5.2 Product Launches and Product Expansions:
7.6 Teva Pharmaceutical Industries Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Approvals and Trials:
7.7 Kyowa Kirin Co., Ltd. (Kirin Company)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Cadila Healthcare Ltd. (Zydus Cadila)
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Apotex, Inc.
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Product Launches and Product Expansions:
7.10 Toksöz Group
7.10.1 Company Overview

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities